Coronary heart disease in Diabetics: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(/* Recommendations for assessing cardiovascular risk in patients with type 2 diabetes{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 39 | pages= 4043-4140 | pmid=37622663 | doi=10.1093/eurheartj/ehad192 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfr...)
(/* 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 39 | pages= 4043-4140 | pmid=37622663 | doi=10.1093/eurheartj/ehad192 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.f...)
Line 24: Line 24:
|}
|}


==2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes<ref name="pmid37622663">{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 39 | pages= 4043-4140 | pmid=37622663 | doi=10.1093/eurheartj/ehad192 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622663  }} </ref>==
==2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes (DO NOT EDIT)<ref name="pmid37622663">{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 39 | pages= 4043-4140 | pmid=37622663 | doi=10.1093/eurheartj/ehad192 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622663  }} </ref>==
===Recommendations for diagnosing diabetes<ref name="pmid37622663">{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 39 | pages= 4043-4140 | pmid=37622663 | doi=10.1093/eurheartj/ehad192 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622663  }} </ref>===  
===Recommendations for diagnosing diabetes(DO NOT EDIT)<ref name="pmid37622663">{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 39 | pages= 4043-4140 | pmid=37622663 | doi=10.1093/eurheartj/ehad192 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622663  }} </ref>===  




Line 38: Line 38:
|}
|}


===Recommendations for assessing cardiovascular risk in patients with type 2 diabetes<ref name="pmid37622663">{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 39 | pages= 4043-4140 | pmid=37622663 | doi=10.1093/eurheartj/ehad192 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622663  }} </ref>===
===Recommendations for assessing cardiovascular risk in patients with type 2 diabetes(DO NOT EDIT)<ref name="pmid37622663">{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 39 | pages= 4043-4140 | pmid=37622663 | doi=10.1093/eurheartj/ehad192 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37622663  }} </ref>===


{|class="wikitable"
{|class="wikitable"

Revision as of 07:19, 21 December 2023

2016 ADA Guideline Recommendations

Types of Diabetes Mellitus

Main Diabetes Page

Diabetes type I

Diabetes type II

Gestational Diabetes Mellitus

2016 ADA Standard of Medical Care Guideline Recommendations

Strategies for Improving Care

Classification and Diagnosis of Diabetes

Foundations of Care and Comprehensive Medical Evaluation

Diabetes Self-Management, Education, and Support
Nutritional Therapy

Prevention or Delay of Type II Diabetes

Glycemic Targets

Obesity Management for Treatment of Type II Diabetes

Approaches to Glycemic Treatment

Cardiovascular Disease and Risk Management

Hypertension and Blood Pressure Control
Lipid Management
Antiplatelet Agents
Coronary Heart Disease

Microvascular Complications and Foot Care

Diabetic Kidney Disease
Diabetic Retinopathy
Diabetic Neuropathy
Diabetic Footcare

Older Adults with Diabetes

Children and Adolescents with Diabetes

Management of Cardiovascular Risk Factors in Children and Adolescents with Diabetes
Microvascular Complications in Children and Adolescents with Diabetes

Management of Diabetes in Pregnancy

Diabetes Care in the Hospital Setting

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shivani Chaparala M.B.B.S [2]; Seyedmahdi Pahlavani, M.D. [3]; Tarek Nafee, M.D. [4]

2016 ADA Standards of Medical Care in Diabetes Guidelines[1]

Screening

"1.In asymptomatic patients, routine screening for coronary artery disease is not recommended as it does not improve outcomes as long as atherosclerotic cardiovascular disease risk factors are treated (Level of Evidence: A)"
"2. Consider investigations for coronary artery disease in the presence of any of the following: atypical cardiac symptoms (e.g., unexplained dyspnea, chest discomfort); signs or symptoms of associated vascular disease including carotid bruits, transient ischemic attack, stroke, claudication, or peripheral arterial disease; or electrocardiogram abnormalities (e.g., Q waves) (Level of Evidence: E)"

Treatment

"1.In patients with known atherosclerotic cardiovascular disease, use aspirin and statin therapy (if not contraindicated) "(Level of Evidence: A)" and consider ACE inhibitor therapy. (Level of Evidence: C) to reduce the risk of cardiovascular events."
"2.In patients with prior myocardial infarction, b-blockers should be continued for at least 2 years after the event (Level of Evidence: B)"
"3.In patients with symptomatic heart failure, thiazolidinedione treatment should not be used (Level of Evidence: A)"
"4.In patients with type 2 diabetes with stable congestive heart failure, metformin may be used if renal function is normal but should be avoided in unstable or hospitalized patients with congestive heart failure (Level of Evidence: B)"

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes (DO NOT EDIT)[2]

Recommendations for diagnosing diabetes(DO NOT EDIT)[2]

Class I
"1.Screening for diabetes is recommended in all individuals with CVD, using fasting glucose and/or HbA1C[3][4][5][6] (Level of Evidence: A)"
”2.It is recommended that the diagnosis of diabetes is based on HbA1C and/or fasting plasma glucose, or on an OGTT if still in doubt[7][8][9](Level of Evidence: B)"

Recommendations for assessing cardiovascular risk in patients with type 2 diabetes(DO NOT EDIT)[2]

Class I
"1. It is recommended to screen patients with diabetes for the presence of severe TOD (target organ damage)[10][11](Level of Evidence: A)"
”2.It is recommended to asses medical history and the presence of symptoms suggestive of ASCVD (Atherosclerotic cardiovascular disease) in patients with diabetes[12][13][14](Level of Evidence: B)"
”3.In patients with T2DM without symptomatic ASCVD or severe TOD, it is recommended to estimate 10-year CVD risk via SCORE2-Diabetes[15](Level of Evidence: B)"

References

  1. ↑ "care.diabetesjournals.org" (PDF).
  2. ↑ 2.0 2.1 2.2 Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ; et al. (2023). "2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes". Eur Heart J. 44 (39): 4043–4140. doi:10.1093/eurheartj/ehad192. PMID 37622663 Check |pmid= value (help).
  3. ↑ American Diabetes Association (2021). "2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021". Diabetes Care. 44 (Suppl 1): S15–S33. doi:10.2337/dc21-S002. PMID 33298413 Check |pmid= value (help).
  4. ↑ Colagiuri S, Lee CM, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K; et al. (2011). "Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes". Diabetes Care. 34 (1): 145–50. doi:10.2337/dc10-1206. PMC 3005450. PMID 20978099.
  5. ↑ Sattar N, Preiss D (2016). "Diabetic microvascular complications as simple indicators of risk for cardiovascular outcomes and heart failure". Lancet Diabetes Endocrinol. 4 (7): 555–6. doi:10.1016/S2213-8587(16)30097-3. PMID 27216887.
  6. ↑ Mak KH, Vidal-Petiot E, Young R, Sorbets E, Greenlaw N, Ford I; et al. (2022). "Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities". Eur J Prev Cardiol. 28 (16): 1795–1806. doi:10.1093/eurjpc/zwab011. PMID 35022686 Check |pmid= value (help).
  7. ↑ Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003). "Report of the expert committee on the diagnosis and classification of diabetes mellitus". Diabetes Care. 26 Suppl 1: S5–20. doi:10.2337/diacare.26.2007.s5. PMID 12502614.
  8. ↑ Cowie CC, Rust KF, Byrd-Holt DD, Gregg EW, Ford ES, Geiss LS; et al. (2010). "Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006". Diabetes Care. 33 (3): 562–8. doi:10.2337/dc09-1524. PMC 2827508. PMID 20067953.
  9. ↑ Arslanian S, Bacha F, Grey M, Marcus MD, White NH, Zeitler P (2018). "Evaluation and Management of Youth-Onset Type 2 Diabetes: A Position Statement by the American Diabetes Association". Diabetes Care. 41 (12): 2648–2668. doi:10.2337/dci18-0052. PMC 7732108 Check |pmc= value (help). PMID 30425094.
  10. ↑ Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ; et al. (2012). "Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis". Lancet. 380 (9854): 1662–73. doi:10.1016/S0140-6736(12)61350-6. PMC 3771350. PMID 23013602.
  11. ↑ Brownrigg JR, Hughes CO, Burleigh D, Karthikesalingam A, Patterson BO, Holt PJ; et al. (2016). "Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study". Lancet Diabetes Endocrinol. 4 (7): 588–97. doi:10.1016/S2213-8587(16)30057-2. PMID 27216886.
  12. ↑ Ling J, Koye D, Buizen L, Khunti K, Montvida O, Paul SK (2021). "Temporal trends in co-morbidities and cardiometabolic risk factors at the time of type 2 diabetes diagnosis in the UK". Diabetes Obes Metab. 23 (5): 1150–1161. doi:10.1111/dom.14323. PMID 33496366 Check |pmid= value (help).
  13. ↑ Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N (2011). "Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors". Arch Intern Med. 171 (5): 404–10. doi:10.1001/archinternmed.2011.2. PMID 21403036.
  14. ↑ Nelson AJ, Peterson ED, Pagidipati NJ (2019). "Atherosclerotic cardiovascular disease and heart failure: Determinants of risk and outcomes in patients with diabetes". Prog Cardiovasc Dis. 62 (4): 306–314. doi:10.1016/j.pcad.2019.07.001. PMID 31301314.
  15. ↑ SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration (2023). "SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe". Eur Heart J. 44 (28): 2544–2556. doi:10.1093/eurheartj/ehad260. PMC 10361012 Check |pmc= value (help). PMID 37247330 Check |pmid= value (help).

Template:WHTemplate:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Coronary_heart_disease_in_Diabetics&oldid=1736686"